Pediatric Promise: China Bets On Better Medicines Amid Three Child Policy Roll-Out
But Industry Incentives Still Limited
As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.
You may also be interested in...
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.